A case of recalcitrant silicone granuloma treated with adalimumab: A case report

Orli M Silverberg; Benoit M Cyrenne; David Croitoru; Matthew K Sandre; Kucy Pon

doi:10.1177/2050313X221093444

A case of recalcitrant silicone granuloma treated with adalimumab: A case report

SAGE Open Med Case Rep. 2022 May 11:10:2050313X221093444. doi: 10.1177/2050313X221093444. eCollection 2022.

Authors

Orli M Silverberg¹, Benoit M Cyrenne^{2

3}, David Croitoru², Matthew K Sandre², Kucy Pon^{1

2

4}

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
³ Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
⁴ Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Abstract

Liquid silicone is a relatively inexpensive injectable used for soft tissue augmentation. Injection of silicone is associated with a risk of delayed granuloma formation associated with elevated levels of tumour necrosis factor-α. We report a case of recalcitrant silicone granulomas following facial injections of silicone successfully treated with tumour necrosis factor-α blockade. Our case, as well as previous reports, demonstrates the effectiveness of this therapy for the treatment of foreign body granulomas from due to silicone.

Keywords: Silicone granuloma; adalimumab; granulomatous inflammation; recalcitrant silicone granuloma; tumour necrosis factor-α inhibitor.

Publication types

Case Reports